Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer.
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
08
2022
revised:
29
09
2022
accepted:
05
10
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Sentinel lymph node (SLN) mapping is a highly accurate surgical technique for detecting metastases in endometrial cancer. The objective of this study was to identify clinical factors associated with failed mapping. All patients with endometrial cancer undergoing minimally-invasive staging and planned SLN biopsy from 1/1/2017 to 12/31/2020 at a single institution were identified retrospectively. Demographic, clinicopathologic and treatment data were obtained. Data were compared using descriptive statistics. Univariate and multivariable logistic regression were performed to identify predictors of failed mapping. 819 patients were identified with a mean age of 64.6 years (range 26-93) and mean BMI of 35.6 kg/m SLN mapping has a high success in patients undergoing minimally-invasive surgical staging for endometrial cancer. Increasing BMI, high risk histology, and lymph node metastases are risk factors for failed mapping.
Identifiants
pubmed: 36249905
doi: 10.1016/j.gore.2022.101080
pii: S2352-5789(22)00160-6
pmc: PMC9554829
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101080Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Natl Compr Canc Netw. 2014 Feb;12(2):248-80
pubmed: 24586086
Int J Gynecol Cancer. 2020 Nov;30(11):1713-1718
pubmed: 32868384
Gynecol Oncol. 2022 May;165(2):215-222
pubmed: 35314087
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Gynecol Oncol. 2019 Oct;155(1):34-38
pubmed: 31402166
Eur J Surg Oncol. 2015 Dec;41(12):1659-63
pubmed: 26433709
Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-315
pubmed: 25004343
Am J Obstet Gynecol. 2000 Jun;182(6):1506-19
pubmed: 10871473
Gynecol Oncol. 2019 Jun;153(3):500-504
pubmed: 30902369
Int J Gynecol Cancer. 2021 Jan;31(1):85-91
pubmed: 33243776
Arch Gynecol Obstet. 2019 Jun;299(6):1667-1672
pubmed: 30927059
Lancet Oncol. 2011 May;12(5):469-76
pubmed: 21489874
Gynecol Oncol. 2020 Aug;158(2):375-381
pubmed: 32499070
Breast J. 2005 May-Jun;11(3):188-94
pubmed: 15871704
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Gynecol Oncol. 2017 Aug;146(2):405-415
pubmed: 28566221